

**Date: 23<sup>rd</sup> September 2026**

|                                                                                                                                                                                                        |                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>To,</b><br>Manager - Listing Compliance<br><b>National Stock Exchange of India Limited</b> , Exchange Plaza. C-1, Block G,<br>Bandra Kurla Complex, Bandra (E),<br>Mumbai - 400 051<br>SYMBOL: JSLL | <b>To,</b><br>Head – Listing Operations<br>Corporate Relationship Department,<br><b>BSE Limited</b><br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai 400001<br>SCRIP Code: 544476 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Subject: Intimation of In-principle approval received from BSE Limited for listing of up to a maximum of 6,50,000 Equity Shares of Rs. 2/-each of Jeena Sikho Lifecare Limited to be issued under Jeena Sikho Employees Stock Option Scheme, 2024 (“ESOS 2024”).**

**Dear Sir/Madam,**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI Listing Regulations”), we wish to inform you that **BSE Limited (“BSE”) has granted in-principle approval to the Company for listing upto a maximum of 6,50,000 Equity Shares of Rs. 2/- each** under the “Jeena Sikho Lifecare Limited Employee Stock Option Scheme 2024” (“ESOS 2024”).

The Company had earlier received in-principle approval from **National Stock Exchange of India Limited (“NSE”) vide letter Ref. No. NSE/LIST/40419** dated 14th March, 2024, in respect of the Equity Shares proposed to be issued pursuant to exercise of Options under ESOS 2024, at a time when the Equity Shares of the Company were listed only on NSE.

Subsequently, upon listing of the Equity Shares of the Company on BSE, the Company made the requisite application to BSE for grant of in-principle approval. Accordingly, **BSE vide its letter Ref. No. DCS/ESOP/IP/RD/239/2026-27 dated 22nd September, 2026, has granted in-principle approval for listing of up to a maximum of 6,50,000 Equity Shares of face value of ₹2/- each**, proposed to be issued pursuant to exercise of Options under ESOS 2024.

The Company has accordingly obtained the requisite **in-principle approvals from both NSE and BSE** in respect of the Equity Shares proposed to be issued pursuant to exercise of Options under ESOS 2024.

It may be noted that pursuant to the sub-division (stock split) of the Equity Shares of the Company from face value of ₹10/- each to face value of ₹2/- each, the original 1,30,000 Equity Shares approved under ESOS 2024 stand adjusted to 6,50,000 Equity Shares of face value of ₹2/- each.

## **JEENA SIKHO LIFECARE LIMITED**

120+ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

### **Registered Office Address:**

SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,  
Punjab-140604, 01762-513185  
CIN NO.: L52601PB2017PLC046545

### **Corporate Office Address:**

B-26, Opp. Metro Pillar No. 223, Rohtak Road,  
New Multan Nagar, Delhi - 110056  
Email ID: cs@jeenasikho.com | www.jeenasikho.com

A copy of the in-principle approval letter received from BSE is enclosed herewith for your information and records. The said information will also be uploaded on the website of the Company at [www.jeenasikho.com](http://www.jeenasikho.com).

You are requested to kindly take the above information on record.

Thanking you,

Yours faithfully,

**For Jeena Sikho Lifecare Limited**

**Manish Grover**  
**Managing Director**  
**DIN: 07557886**

**Place: Zirakpur, Punjab**  
**Date: 23.09.2026**

**Encl.: A/A**

## **JEENA SIKHO LIFECARE LIMITED**

120+ AYURVEDA CLINICS & HOSPITALS | FREEDOM FROM 2D DISEASES & DRUGS

**Registered Office Address:**

SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,  
Punjab-140604, 01762-513185  
CIN NO.: L52601PB2017PLC046545

**Corporate Office Address:**

B-26, Opp. Metro Pillar No. 223, Rohtak Road,  
New Multan Nagar, Delhi - 110056  
Email ID: [cs@jeenasikho.com](mailto:cs@jeenasikho.com) | [www.jeenasikho.com](http://www.jeenasikho.com)

DCS/ESOP/IP/RD/239/2026-27

September 22, 2026

To,  
The Company Secretary  
**Jeena Sikho Lifecare Limited**  
SCO 11, First Floor, Kalgidhar Enclave,  
Zirakpur, Mohali, Punjab – 140 604.

Dear Sir/Madam,

**Re: Application of In-principle approval for 6,50,000 Equity shares of Rs.2/- each to be issued under 'JEENA SIKHO EMPLOYEES STOCK OPTION SCHEME 2024 ("SCHEME"/ "ESOS SCHEME"/ "ESOS 2024")'**

We acknowledge the receipt of your letter on the captioned matter regarding in-principle approval for issue and allotment of 6,50,000 Equity shares of Rs.2/- to the permanent employees of the Company and the employees of the group company(ies) including its subsidiary/(ies) and holding company as per the undertaking provided under 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021) to be allotted by the Company, upon exercise of stock options in terms of Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, together with copy of statement under Regulation 10(b) and other enclosures. In this regard, the Exchange is pleased to grant in-principle approval for issue and allotment of a maximum of 6,50,000 equity shares, which are likely to arise out of exercise of options as and when exercised under the Scheme subject to the Company fulfilling the following conditions:

1. The Company shall notify the Exchange as per the format prescribed under Regulation 10(c) of Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 together with listing application after the shares were allotted and the same are credited to the beneficiaries account or share certificates have been dispatched, as may be applicable.
2. Payment of fees as may be prescribed from time to time.
3. Receipt of statutory and other approvals and compliance of guidelines issued by the statutory authorities including SEBI, RBI, and MCA etc.
4. Compliance to all guidelines/regulations/directions of the Exchange or any statutory authorities, documentary requirements from time to time.
5. Compliance of all conditions of Listing Agreement as on date of Listing.
6. Compliance to the Companies Act, 1956 / 2013 and other applicable laws.
7. Submissions of documents as given in the Checklist available on the BSE website under link <http://www.bseindia.com/static/about/downloads.aspx?expandable=2>

The Exchange reserves its right to withdraw its in-principle approval at any later stage if the information submitted to the Exchange is found to be incomplete / incorrect / misleading / false or for any contravention of Rules, Bye-laws and Regulations of the Exchange, Listing Agreement, Guidelines/Regulations issued by statutory authorities etc. Kindly note that the Exchange will issue trading permission from time to time upon receipt of notification under Regulation 10(c) and subject to the compliance of the conditions as stated above.

Yours faithfully,



**Nitinkumar Pujari**  
**Assistant Vice President**



**Abhishek Kadlak**  
**Deputy Manager**